News

Sun Pharma to introduce its version of Vortioxetine in India

Enters into exclusive patent licence with Lundbeck

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H Lundbeck to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIFTM. The territory of the licensing agreement will only cover India. 

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia. 

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, “Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap. MDD is a serious and complicated disorder and VORTIDIFTM will serve as an important novel treatment option for patients in India.”

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close